{"id":28934,"date":"2025-03-09T19:09:59","date_gmt":"2025-03-09T11:09:59","guid":{"rendered":"https:\/\/flcube.com\/?p=28934"},"modified":"2025-03-09T19:10:01","modified_gmt":"2025-03-09T11:10:01","slug":"newco-model-chinas-innovative-drug-companies-new-transaction-mode-in-capital-winter","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28934","title":{"rendered":"NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter"},"content":{"rendered":"\n

NewCo is a new transaction model developed by Chinese innovative drug companies in response to capital winter and internationalization needs. It involves licensing overseas rights of early-stage R&D pipelines to newly established independent companies, bringing in overseas capital and management teams to accelerate development and share risks. This model combines “product licensing + equity” to secure funding while retaining equity for long-term gains.<\/p>\n\n\n\n

Core Mechanisms and Benefits<\/strong>
The NewCo model offers four main advantages:<\/p>\n\n\n\n

    \n
  1. Risk Isolation<\/strong>: Spin off high-risk projects to avoid dragging down parent companies.<\/li>\n\n\n\n
  2. Leverage Capital<\/strong>: Attract overseas funds, with 2024’s NewCo upfront payments reaching $3.8 billion, surpassing IPO fundraising.<\/li>\n\n\n\n
  3. Efficiency Boost<\/strong>: For example, Keymed Biosciences advanced CM336 from Phase I to Phase II in 18 months via NewCo, nearly half the traditional time.<\/li>\n\n\n\n
  4. Ecosystem Restructuring<\/strong>: Traditional pharma (like Hengrui) focuses on core areas, while biotechs (like Allist Pharmaceuticals) diversify risks and monetize quickly.<\/li>\n<\/ol>\n\n\n\n

    Typical Cases<\/strong>
    Several notable NewCo transactions have occurred:<\/p>\n\n\n\n

      \n
    1. Hengrui Pharmaceuticals \u00d7 Hercules<\/strong>: Licensed GLP-1 assets with upfront $110 million and potential total $6 billion, retaining 19.9% equity.<\/li>\n\n\n\n
    2. Keymed Biosciences’ Transactions<\/strong>: Licensed CM336 to Platina Medicines, CM313 to Timberlyne Therapeutics, and co-licensed ICP-B02 with InnoCare Pharma.<\/li>\n\n\n\n
    3. Genor Biopharma \u00d7 TRC 2004<\/strong>: Licensed GB261’s overseas rights with upfront tens of millions and potential $443 million.<\/li>\n\n\n\n
    4. EpimAb Biotherapeutics \u00d7 Vignette Bio<\/strong>: Licensed EMB-06 with upfront $60 million and potential total $575 million.<\/li>\n\n\n\n
    5. Harbour BioMed\/Kelun-Biotech \u00d7 Windward Bio<\/strong>: Jointly licensed SKB378\/HBM9378 with upfront $450 million and potential total $970 million.<\/li>\n\n\n\n
    6. Sciwind Bioscience \u00d7 Verdiva Bio<\/strong>: Licensed GLP-1 oral delivery technology with upfront $70 million and potential total $2.4 billion.<\/li>\n<\/ol>\n\n\n\n

      Impact and Risks<\/strong>
      NewCo has gained attention as a lifeline in the capital winter, driving tangible impacts:<\/p>\n\n\n\n